Here is a SARS-CoV-2 study undertaken right here in Victoria that IMO further supports the need for the additional phase 3 COVID-19 ARDS trial using Remestemcel-L .... the 12 month data from the first phase 3 COVID-19 ARDS trial could also demonstrate whether patients treated with Remestemcel-L had better outcomes in these highlighted areas ?
If you look at the findings summary paragraph below one might also draw the conclusion (long bow I know) that there may be an increased demand for treatments like Rexlemestrocel-L in the future given the elevated risks for heart related problems associated with patients hospitalised with SARS-CoV-2 ?
Interesting study nonetheless if anyone wants to have a read as you can download the full 32 page paper for free at the end of the article.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4025054
Complications Following SARS-CoV-2 Infection in Victoria, Australia: A Record Linkage Study
31 Pages Posted: 3 Feb 2022
Abstract
Background: SARS-CoV-2 infection can induce significant pathologies including neurological, cardiac and vascular disease events. We assessed strength of association between SARS-CoV-2 infection and several key respiratory and non-respiratory complications in Victoria, Australia.
Methods: Record linkage was used to assemble all laboratory-confirmed COVID-19 cases notified 1 January 2020–31 May 2021 with corresponding hospitalisation episodes to 30 September 2021. Hospitalisation rates and reasons for hospitalisation among cases was assessed using a cohort study design. A self-controlled case series was used to assess strength of association between SARS-CoV-2 infection and several outcomes in the first 90 days following COVID-19 illness onset. Incident rate ratios (IRR) and 95% confidence intervals were calculated comparing risk in the post-exposure period with a baseline period prior to SARS-CoV-2 infection.
Findings: There were 20,594 COVID-19 cases, with 2,992 (14·53%) related hospitalisation s. In the 90-days following COVID-19 illness onset, elevated risks were observed for myocarditis and pericarditis (IRR: 14·76, 95% confidence interval 3·19–68·30); thrombocytopenia (IRR: 7·38, 4·36–12·50), pulmonary embolism (IRR: 6·37; 3·55–11·43), acute myocardial infarction (IRR: 3·89, 2·59–5·84) and cerebral infarction and non-ischemic stroke (IRR: 2·31, 1·37–3·90).
Interpretation: There is a strong association between SARS-CoV-2 infection and risk of several complications highlighting the value of COVID-19 pandemic mitigation measures such as vaccination. Improved awareness of these risks may support early diagnosis and management of patients with a past history of SARS-CoV-2 infection, and contribute to a greater understanding of the public health burden of COVID-19.
Funding Information: No funding was provided for this study.
- Forums
- ASX - By Stock
- MSB
- RWE for 2nd MSB COVID-19 ARDS P3 Trial
RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-233
-
- There are more pages in this discussion • 673 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.01 |
Change
0.030(3.06%) |
Mkt cap ! $1.153B |
Open | High | Low | Value | Volume |
$1.01 | $1.04 | 99.0¢ | $5.111M | 5.050M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 211966 | $1.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.02 | 136540 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 48333 | 1.005 |
3 | 49000 | 1.000 |
3 | 80800 | 0.995 |
5 | 129515 | 0.990 |
1 | 3300 | 0.985 |
Price($) | Vol. | No. |
---|---|---|
1.020 | 136540 | 9 |
1.025 | 63000 | 3 |
1.030 | 28077 | 3 |
1.040 | 27850 | 2 |
1.045 | 103431 | 6 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |